ER vs. IR [Design Issues]

posted by Dr_Dan  – 2019-12-19 09:01 (643 d 03:30 ago) – Posting: # 21004
Views: 2,308

Hi Helmut
your statement only holds true in your example with different strengths. If you have only one or the highest IR strength then my statement applies. The once daily (or 8 h) dosing of the ER formulation does not have to mimicry the performance of the multiple dosing of the IR formulation if you can show that there is a well-defined therapeutic window in terms of safety and efficacy and the rate of input is known not to influence the safety and efficacy profile or the risk for tolerance development.

Kind regards and have a nice day

Complete thread:

 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Wednesday 13:32 CEST (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz